Nasus Pharma Ltd.

Formulex Pharma Innovations Ltd.

Tair Lapidot

Dalia Megiddo

Galia Temtsin-Krayz

Carolina Abrutzky

Dry powder pharmaceutical compositions for intranasal administration include an opioid receptor antagonist, e.g. naloxone, as active ingredient, and dosage unit forms thereof. Methods of treating opioid overdose include administering the dry powder compositions.

Dry powder compositions for intranasal delivery

A pharmaceutical composition in a form of dry powder for intranasal administration includes solid particles of at least one opioid receptor antagonist as active ingredient and two types of solid particles. A naloxone pharmaceutical composition in the form of dry powder for intranasal administration, including as active agent naloxone or a pharmaceutically acceptable salt thereof. A kit for intranasal administration of naloxone. A method of treating opioid overdose/intoxication and/or a symptom thereof in a patient in need thereof by intranasally administering a therapeutically effective amount of a composition including solid particles of at least one opioid receptor antagonist as active ingredient and two types of solid particles.

Growing community of inventors

Lapid, Israel

Tair Lapidot